Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
주식 순위 #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
주가
$4.74
마지막 동기화: 2026-08-31
시가총액
$372.19M
변동 (1일)
-2.47%
변동 (1년)
-1.04%
국가
US
거래 Lexeo Therapeutics, Inc. Common Stock (LXEO)

카테고리

Lexeo Therapeutics, Inc. Common Stock (LXEO)의 주가 이력
최고 종가: $4.91 (2026-08-01 기준)

최저 종가: $11.06 (2023-11-01 기준)
Lexeo Therapeutics, Inc. Common Stock의 주가 이력 (2023 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$745.74 4.52%
CH